NIH Offers $5M for Biomarker Studies of Alzheimer's Progression in Down Syndrome | GenomeWeb

NEW YORK (GenomeWeb) – The National Institutes of Health will award up to $5 million next fiscal year to fund one or two research teams that will use a range of biomarker typesto identify the progression of Alzheimer's disease in adults who have Down syndrome.

Adults with Down syndrome are at "extremely high risk" of developing AD, NIH said in a funding announcement on Friday. These projects will seek to characterize the longitudinal trajectory of AD-related genetic, biochemical, imaging, clinical, and cognitive biomarkers in adults with Down syndrome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.